-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The heterogeneity of tumor is one of the characteristics of malignant tumor, which refers to the tumor in the process of growth, after many division and proliferation, its subcellular shows molecular biology or genetic changes, so that the growth rate of the tumor, invasive ability, sensitivity to drugs, prognosis and other aspects of difference.
can have many different genotypes or subtypes of cells in the same tumor.
in invasive tumors, there are "leading cells" and "follow cells", two cell subgroups that work together during tumor metastasis.
recently, a team of researchers found that a tiny "finger"-like protrusion called a silky pseudo-foot drives aggressive behavior in lung cancer cells, and leading cells have longer "fingers" than follow-up cells.
based on this finding, they have developed an innovative technique that isolates leading and followed cells.
this is very important for the precise treatment of tumors.
the study, led by Adam Marcus, professor of heterology and oncology medicine at Emory University, and published in Science Advances on July 24, 2020, entitled "Epigenetically heterogeneous ousthae direct individual strus ous through filopodia-drivennectentinmicroting" the findings help researchers develop a treatment to prevent the spread of cancer by understanding the rare cells necessary for fatal tumor metastasis.
Marcus says persistent epigenetic changes that distinguish leading cells from aggressive behavior can occur in several types of cancer.
Marcus's previous research has shown how leading cells and more commonly related cells (follow cells) work together to form an invasive cell population.
the migration and survival rates of these two tumor cells depend on each other, but have different gene activity patterns and even different shapes.
in particular, leading cells show longer filamentous feet than follow editing cells.
the researchers said: "The silky pseudo-foot, like the fingers of a cell, helps the cell move forward.
" they also found that silky pseudo-foot length is associated with a gene called MYO10, which encodes an ingredient in the internal cytoskeleton that stabilizes the filament-like pseudo-foot.
myO10 is the gene with the highest expression and methylation in leading cells compared to followed cells, while filamentous pseudo-foot and invasive behavior depend on the activity of MYO10. "It is well known that MYO10 is associated with invasion and metastasis, but this is the first evidence that it plays this particular role in a rare cell subgroup," said Marcus,
.
helps us find these rare cells in patient tumors to determine their potential aggression.
" leading cells also secrete fibrous binding proteins, a viscous extracellular protein, while followed cells do not secrete.
myO10 protein helps the filamented pseudo-foot rearrange the fibrinoprotein molecules into fibers, but it does not appear to interact directly with fibrous-binding proteins. "When the current linear cell filament-like pseudo-foot pulls the extracellular matrix, they transform the matrix from a random mesh structure into a long, parallel orbit in front of the cell, paving the way for cell population movement," the
researchers said.
" filamented pseudo-foot is sometimes described as a precursor to a tentacle-like or more stable cellular structure. "We observed that in the leading cells, silky pseudo-foot is not only a sensor in the extracellular environment, but also actively involved in the recombination of extracellular matrix," said Marcus,
.
" the researchers also explored other changes in identifying leading cells, such as the increase in gene expression in Jagged1.
a receptor of the Jagged1 encoding Notch pathway, whose activity depends on the activation of MYO10.
MYO10 and Jagged/Notch activation may be extended to patient samples and other types of cancer.
.